FDA pharmacologic class
Programmed Death Ligand-1 Blocker
3 medicines are in FDA's class of programmed death ligand-1 blockers: durvalumab (Imfinzi), avelumab (Bavencio) and cosibelimab (Unloxcyt). 0 of the 3 are listed from generic labelers (FDA NDC Directory, October 8, 2026).
Which medicines are programmed death ligand-1 blocker?
| Medicine | Brand names | Generic labelers (all forms) | Pharmacy cost | Boxed warning | Shortage | Recalls since 2012 |
|---|---|---|---|---|---|---|
| Durvalumab | Imfinzi | none listed | n/a | No | No current entry | 1 |
| Avelumab | Bavencio | none listed | n/a | No | No current entry | 0 |
| Cosibelimab | Unloxcyt | none listed | n/a | No | No current entry | 0 |
Source: FDA Established Pharmacologic Class (NDC Directory, openFDA); CMS NADAC of October 7, 2026; FDA shortages and recalls (FDA files October 8, 2026)